Immunic Inc. [IMUX] Is Currently -2.85 below its 200 Period Moving Avg: What Does This Mean?

Immunic Inc. [NASDAQ: IMUX] traded at a low on 10/20/22, posting a -2.85 loss after which it closed the day’ session at $9.20. The company report on October 20, 2022 that Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


– Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo –.

– No New Safety Signals Observed for IMU-935 in this Trial –.

The results of the trading session contributed to over 8440752 shares changing hands. Over the past one week, the price volatility of Immunic Inc. stands at 12.26% while the volatility over the past one month is 16.83%.

The market cap for IMUX stock reached $302.77 million, with 30.25 million shares outstanding and 25.27 million shares in the current float. Compared to the average trading volume of 2.28M shares, IMUX reached a trading volume of 8440752 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Immunic Inc. [IMUX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMUX shares is $23.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMUX stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Immunic Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 19, 2022. While these analysts kept the previous recommendation, Aegis Capital raised their target price to Buy. The new note on the price target was released on April 15, 2021, representing the official price target for Immunic Inc. stock. Previously, the target price had yet another raise to $55, while JMP Securities analysts kept a Mkt Outperform rating on IMUX stock.

The Average True Range (ATR) for Immunic Inc. is set at 1.03 The Price to Book ratio for the last quarter was 2.17, with the Price to Cash per share for the same quarter was set at 2.68.

How has IMUX stock performed recently?

Immunic Inc. [IMUX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.81. With this latest performance, IMUX shares gained by 175.45% in over the last four-week period, additionally plugging by 13.16% over the last 6 months – not to mention a rise of 9.13% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMUX stock in for the last two-week period is set at 71.07, with the RSI for the last a single of trading hit 70.08, and the three-weeks RSI is set at 69.96 for Immunic Inc. [IMUX]. The present Moving Average for the last 50 days of trading for this stock 5.14, while it was recorded at 9.58 for the last single week of trading, and 7.32 for the last 200 days.

Immunic Inc. [IMUX]: Deeper insight into the fundamentals

Return on Equity for this stock declined to -65.02, with Return on Assets sitting at -60.56.

Immunic Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.10 and a Current Ratio set at 10.10.

Earnings analysis for Immunic Inc. [IMUX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMUX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Immunic Inc. go to 15.50%.

Insider trade positions for Immunic Inc. [IMUX]

There are presently around $168 million, or 60.90% of IMUX stock, in the hands of institutional investors. The top three institutional holders of IMUX stocks are: RTW INVESTMENTS, LP with ownership of 2,761,968, which is approximately 2.087% of the company’s market cap and around 0.20% of the total institutional ownership; OMEGA FUND MANAGEMENT, LLC, holding 1,788,160 shares of the stock with an approximate value of $16.45 million in IMUX stocks shares; and POINT72 ASSET MANAGEMENT, L.P., currently with $12.19 million in IMUX stock with ownership of nearly 82.759% of the company’s market capitalization.

35 institutional holders increased their position in Immunic Inc. [NASDAQ:IMUX] by around 5,294,973 shares. Additionally, 49 investors decreased positions by around 4,617,077 shares, while 13 investors held positions by with 8,353,237 shares. The mentioned changes placed institutional holdings at 18,265,287 shares, according to the latest SEC report filing. IMUX stock had 18 new institutional investments in for a total of 2,094,650 shares, while 23 institutional investors sold positions of 2,118,917 shares during the same period.


Please enter your comment!
Please enter your name here